Status:
COMPLETED
Baseline Epidemiologic Assessment of Abuse-Deterrence of MorphaBond Extended Release (BEAD-MB)
Lead Sponsor:
Daiichi Sankyo
Conditions:
Baseline Epidemiologic Assessment
Eligibility:
All Genders
Brief Summary
The main objectives of this study are to provide surveillance/descriptive data to (a) assess utilization of MorphaBond ER and selected comparators overall and by age group and census regions using nat...
Detailed Description
The study started after the launch of MorphaBond ER in October 2017 and will continue until September 2020 and the final study report will be submitted to the FDA by December 2020. This is an observa...
Eligibility Criteria
Inclusion
- Male or female
- MorphaBond ER users or relevant comparator users
Exclusion
- Not applicable
Key Trial Info
Start Date :
October 16 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2020
Estimated Enrollment :
17566 Patients enrolled
Trial Details
Trial ID
NCT04033094
Start Date
October 16 2017
End Date
December 31 2020
Last Update
March 15 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Daiichi Sankyo, Inc.
Basking Ridge, New Jersey, United States, 07920